Overview

Autologous Transplant in HIV Patients (BMT CTN 0803)

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients with HIV.
Phase:
Phase 2
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Heart, Lung, and Blood Institute (NHLBI)
National Marrow Donor Program
Treatments:
Carmustine
Cytarabine
Etoposide
Etoposide phosphate
Melphalan